ArticleDiabetes/metabolism research and reviews2026
Impact of Adverse Metabolic Factors on the Burden of Chronic Kidney Disease in the Chinese Population ≥ 20 Years Old, 1990-2019.
Article in Diabetes/metabolism research and reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of Adverse Metabolic Factors on the Burden of Chronic Kidney Disease in the Chinese Population ≥ 20 Years Old, 1990-2019.Diabetes/metabolism research and reviews · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo quantify temporal trends in chronic kidney disease (CKD) burden attributable to adverse metabolic risk factors among Chinese adults aged ≥ 20 years during 1990-2019. MATERIALS AND
methodsWe used Global Burden of Disease Study 2019 (GBD 2019) estimates for China to assess five CKD causes (CKD due to type 1 diabetes, type 2 diabetes, hypertension, glomerulonephritis, and other/unspecified causes) and three metabolic risks (high systolic blood pressure (SBP), high body mass index (BMI), and high fasting plasma glucose (HFPG)). Outcomes were deaths and disability-adjusted life years (DALYs) (numbers and rates per 100,000), stratified by sex and 13 age groups. Joinpoint regression was used to estimate annual percent change (APC) and average annual percent change (AAPC) in rates from 1990 to 2019.
resultsIn 2019, the mortality rate for CKD attributable to these metabolic risks was 6.87 per 100,000, and total attributable DALYs were 4201 (thousand). Hypertensive nephropathy had the largest attributable burden (mortality 2.5/100,000; DALY rate 59.2/100,000), followed by CKD due to type 2 diabetes. From 1990 to 2019, the overall attributable CKD mortality rate increased (AAPC = 0.55%) while the DALY rate decreased slightly (AAPC = -0.27%). High SBP remained the leading contributor to attributable burden in 2019, whereas high BMI showed the fastest increase in attributable mortality burden over time. Attributable burden increased steeply with age and was higher in males than in females.
conclusionsHigh SBP remains a major driver of CKD burden in China, but the rapidly rising high-BMI-attributable burden highlights the need for integrated prevention focused on blood pressure control and obesity prevention, particularly among older adults and men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.